Dr. Owens is a biotech entrepreneur with an extensive background in venture-backed biopharma companies and particular expertise in pharmaceutical company transactions. Prior to co-founding Atterocor, she served as SVP, Corporate Development & Strategy at Lycera. Dr. Owens also held positions at QuatRx, Tularik and the UCSF OTM. Dr. Owens has a Ph.D. in biochemistry from UCSF and a B.S. in chemistry and B.A. in MCB from UC Berkeley.

Dr. Kerppola is an experienced life sciences professional with skills in business development, strategy, marketing, and economic analysis. In addition to Atterocor, she is CEO of ONL Therapeutics, a pre-seed stage ophthalmic company. Dr. Kerppola previously worked at Express Scripts, Bausch & Lomb, MEDC, Parke-Davis and McKinsey. She earned her Ph.D. in Biochemistry at UC Berkeley, MBA at Columbia, and B.S. at Washington State Univ.

Dr. Phillips served for 8 years as the Chief Medical Officer & SVP Clinical Development for Morphotek, which was acquired by Eisai. He ran multiple phase I through III oncology studies globally on 4 novel compounds. Previously he was at Aventis Behring and held appointments as Assoc Prof of Medicine at Univ of Texas Med School and Assist Prof at Baylor College of Medicine. Dr. Phillips has a BS from Univ of Michigan, MD from Wayne State Univ.